Connect with us

Hi, what are you looking for?

Jewish Business News


Borderfree Files For $100 Million Wall Street IPO

The company has filed a confidential prospectus, the “Wall Street Journal” reports.

Borderfree logo

Almost a year and half after beginning the IPO process,  Borderfree Inc. is approaching a Wall Street offering. The “Wall Street Journal” reports that the company filed a confidential prospectus several months ago, and is set to file a public prospectus soon to raise $100 million. The banks chosen to lead the IPO, at a company valuation of $700-800 million, are Credit Suisse and RBC.

Borderfree has undergone a few transformations since Yuval Tal founded it in 1999. The company started out under the name E4X, and operated in international trade. In 2008, the company changed its name and strategy and became FiftyOne, providing online sales solutions for US fashion and lifestyle brands. In 2012, after acquiring Borderfree, which broadened the business model to include Canada, the company changed its name once again.

Borderfree’s revenue totaled $70 million in 2012, up 75% from 2011. In an interview with “Globes” in late 2012, when “Globes” reported the company’s intention to hold an IPO, CEO Michael DeSimone admitted, “We are exploring the possibility of an IPO.”

Borderfree’s investors include Delta Ventures,  Pitango Venture Capital, Adam Street Partners, and financing from Viola Credit.


Published by Globes [online], Israel business news – 

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.



You May Also Like

World News

In the 15th Nov 2015 edition of Israel’s good news, the highlights include:   ·         A new Israeli treatment brings hope to relapsed leukemia...


After two decades without a rating system in Israel, at the end of 2012 an international tender for hotel rating was published.  Invited to place bids...


The contract signed between the Israeli government and Pfizer shows clearly and unequivocally that this is a clinical study on humans - The agreement...


Now Platika joins and elite club of $10 billion plus Israeli firms.